Optimal Medical Treatment of Difficult-to-treat Hypertension
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2500 participants.
Also called NCT06275763
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,500 participants
- Registry
-
NCT06275763
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Unknown status
Technical summary
Registry record NCT06275763. Randomized; triple masking; primary purpose treatment. Start 2023-10-20 (actual); primary completion 2025-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Medical Treatment of Difficult-to-treat Hypertension
- Acronym
- OPTIMAL-HT
- Condition
- Hypertension
- Intervention (Drug)
- Phase C: Eplerenone
- Intervention (Drug)
- Phase C: Spironolactone
- Intervention (Drug)
- Phase C: Torasemide
- Intervention (Drug)
- Phase B: Triplixam / Elestar HCT
- Intervention (Diagnostic test)
- Phase A: Confirmation of uncontrolled hypertension
- Lead sponsor
- National Institute of Cardiology, Warsaw, Poland
Record details
- Record id
cardio:ct-nct06275763- Content hash
8f51490091dfae5a5786e32c14fd7e544e495b3aeb77647ca310fea4e01037e6